These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 23708653)

  • 21. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
    Chen F; Liu C; Zhang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
    Chen F; Zhang Z; Yu Y; Liu Q; Pu F
    Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
    Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
    Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
    Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
    PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
    Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
    Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.
    Lelliott EJ; Kong IY; Zethoven M; Ramsbottom KM; Martelotto LG; Meyran D; Zhu JJ; Costacurta M; Kirby L; Sandow JJ; Lim L; Dominguez PM; Todorovski I; Haynes NM; Beavis PA; Neeson PJ; Hawkins ED; McArthur GA; Parish IA; Johnstone RW; Oliaro J; Sheppard KE; Kearney CJ; Vervoort SJ
    Cancer Discov; 2021 Oct; 11(10):2582-2601. PubMed ID: 33990344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
    Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
    Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
    Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
    Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
    Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
    Zhang Y; Kim KH; Zhang W; Guo Y; Kim SH; Lü J
    Int J Cancer; 2012 Jan; 130(1):200-12. PubMed ID: 21328348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
    Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
    Liu M; Liu H; Chen J
    Oncol Rep; 2018 Mar; 39(3):901-911. PubMed ID: 29399694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
    de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
    Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
    [No Abstract]   [Full Text] [Related]  

  • 38. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
    Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.